SCHEMBL30714700

SCHEMBL30714700

Cc1ncsc1COc1ccc2nn(C)c(C(=O)NC3(CO)COC3)c2c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 7/20 0.33
MMP3 P08254 2/20 0.33
MMP7 P09237 2/20 0.33
ADAMTS4 O75173 1/20 0.33
ADAMTS1 Q9UHI8 1/20 0.33
ADAMTS5 Q9UNA0 1/20 0.33
HPGD P15428 2/20 0.33
GABRA5 P31644 1/20 0.32
MMP13 P45452 2/20 0.32
MMP2 P08253 1/20 0.32
MMP12 P39900 1/20 0.32
FFAR1 O14842 1/20 0.31
MCHR1 Q99705 2/20 0.31
ALDH1A1 P00352 3/20 0.31
NPC1 O15118 4/20 0.30
RAB9A P51151 4/20 0.30
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714653 0.93 SCN9A (0.36) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL26874590 0.93 ADAM17 (0.39) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL30714695 0.92 ADAM17 (0.35) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL30714754 0.88 HPGD (0.32) ADAM17MMP3HPGDGABRA5MCHR1
SCHEMBL31539872 0.87 HPGD (0.32) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL30714666 0.87 ADAM17 (0.34) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL30714760 0.84 MMP3 (0.32) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL30714626 0.84 PARG (0.34) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL30714728 0.84 CNR2 (0.34) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL30714608 0.82 HPGD (0.32) ADAM17MMP3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 ADAM17 3090/4885MMP3 603/4885MMP7 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.